Endocrine Abstracts

Introduction: Alemtuzumab is an humanized monoclonal antibody used for treatment of Relapsing remitting Multiple Sclerosis (RRMS). One of its main adverse effects is thyroid dysfunction, being a fluctuating hypothyroidism the most frequent presentation. Sometimes this thyroid disturbance is so significant that it might lead to alemtuzumab withdrawal. We present two Clinical cases of hyperthyroidism secondary to alemtuzumab with different clinical courses. <p class="abstext...